Published in Oncotarget on November 10, 2015
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene (2007) 10.08
Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol (1999) 6.58
Targeting mitochondria for cancer therapy. Nat Rev Drug Discov (2010) 4.07
Histone deacetylases, transcriptional control, and cancer. J Cell Physiol (2000) 3.18
Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol (1999) 3.18
Rhabdomyosarcoma: an overview. Oncologist (1999) 2.68
Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther (2009) 2.50
Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature (2006) 2.12
Histone acetylation and disease. Cell Mol Life Sci (2001) 2.11
The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res (1997) 1.76
Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell (2013) 1.72
Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res (2009) 1.42
Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol (2009) 1.21
Rhabdomyosarcoma in children. Curr Opin Pediatr (2009) 1.17
Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene (2009) 1.12
Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. Adv Cancer Res (2012) 1.10
JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res (2009) 1.09
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer (2009) 1.08
Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585. Br J Haematol (2010) 0.97
The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. Leukemia (2009) 0.96
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clin Cancer Res (2013) 0.95
Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma. Oncotarget (2015) 0.92
Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs. Cell Death Differ (2015) 0.88
Advances in therapy for pediatric sarcomas. Curr Oncol Rep (2014) 0.87
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia. Klin Padiatr (2012) 0.87
Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA. Cancer Lett (2014) 0.83
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2013) 0.83
Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines. Anticancer Drugs (2015) 0.77
Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma. Oncotarget (2015) 0.92
Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis. Oncotarget (2016) 0.80
Molecular definitions of autophagy and related processes. EMBO J (2017) 0.79
Cooperative TRAIL production mediates IFNα/Smac mimetic-induced cell death in TNFα-resistant solid cancer cells. Oncotarget (2016) 0.78
Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers. Oncotarget (2016) 0.78
Differential role of RIP1 in Smac mimetic-mediated chemosensitization of neuroblastoma cells. Oncotarget (2015) 0.76
Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics. Oncotarget (2017) 0.76
RSL3 and Erastin differentially regulate redox signaling to promote Smac mimetic-induced cell death. Oncotarget (2016) 0.75
Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines. Oncotarget (2017) 0.75
Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines. Oncotarget (2017) 0.75